9 September 2024
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Notice of Interim Results and Presentation via Investor Meet Company
CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, will announce its Interim Results for the six months ended 30 June 2024 on Thursday, 19 September 2024.
Andrew Webb, CEO of CRISM Therapeutics, will provide a live presentation via Investor Meet Company on 19 September 2024 at 12.00pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 18 September 2024, 9.00am BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet CRISM Therapeutics via: https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor
Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.
-Ends-
Enquiries:
| Company | Nomad and Broker | Financial PR |
| CRISM Therapeutics Corporation | S.P. Angel Corporate Finance LLP | Burson Buchanan |
| Andrew Webb, CEO Chris McConville, CSO | Richard Morrison Adam Cowl | Mark Court / Jamie Hooper CRISM@buchanancomms.co.uk |
| via Burson Buchanan | +44 (0) 20 3470 0470 | +44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed® in high-grade glioma. Based on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.
For more information please visit: https://www.crismtherapeutics.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.